Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 68Recurrence 17Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Renal Insufficiency 2Plasmacytoma 2Myeloproliferative Disorders 2Chromosome 17 deletion 2Amyloidosis 2Thrombocytosis 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Dexamethasone 6fludarabine 5Whole-Body Irradiation 5Mycophenolic Acid 5Melphalan 5Lenalidomide 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Tacrolimus 3Calcium Dobesilate 3Bortezomib 3dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Sirolimus 2Antilymphocyte Serum 2Allopurinol 2pomalidomide 1plerixafor 1pegylated granulocyte colony-stimulating factor 1liposomal doxorubicin 1ixazomib 1isatuximab 1ferric pyrophosphate 1elotuzumab 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Plasma Cell × pomalidomide × Clear all
NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Mayo Clinic

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡